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BACKGROUND: Mendelian randomization data suggest that the genetic 
determinants of lifetime higher triglyceride-rich lipoprotein-cholesterol (TRL-C) are 
causally related to cardiovascular disease and therefore a potential therapeutic target. 
The relevance of TRL-C among patients receiving statins is unknown. We assessed 
the relationship between TRL-C and cardiovascular risk, and whether this risk was 
modifiable among patients receiving statins in the TNT trial (Treating to New Targets).
METHODS: Patients with coronary heart disease and low-density lipoprotein 
cholesterol (LDL-C) 130 to 250 mg/dL entered an 8-week run-in phase with 
atorvastatin 10 mg/d (ATV10). After this period, participants with LDL-C <130 mg/
dL entered the randomized phase with ATV10 (n=5006) versus atorvastatin 80 
mg/d (ATV80, n=4995). The primary end point was coronary heart disease death, 
nonfatal myocardial infarction, resuscitated cardiac arrest, or stroke (major adverse 
cardiovascular events [MACE]). TRL-C was calculated as total cholesterol minus 
high-density lipoprotein cholesterol minus LDL-C. The effect of atorvastatin on TRL-C 
was assessed during the run-in phase (ATV10) and randomized phase (ATV80 versus 
ATV10). The risk of MACE was assessed across quintiles (Q) of baseline TRL-C (and, 
for comparison, by baseline triglycerides and non–high-density lipoprotein cholesterol) 
during the randomized period. Last, the association between TRL-C changes with 
atorvastatin and cardiovascular risk was assessed by multivariate Cox regression.
RESULTS: ATV10 reduced TRL-C 10.7% from an initial TRL-C of 33.9±16.6 mg/dL. 
ATV80 led to an additional 15.4% reduction. Cardiovascular risk factors positively 
correlated with TRL-C. Among patients receiving ATV10, higher TRL-C was associated 
with higher 5-year MACE rates (Q1=9.7%, Q5=13.8%; hazard ratio Q5-versus-Q1, 
1.48; 95% confidence interval, 1.15–1.92; P-trend<0.0001). ATV80 (versus ATV10) 
did not significantly alter the risk of MACE in Q1-Q2, but significantly reduced risk 
in Q3-Q5 (relative risk reduction, 29%–41%; all P<0.0250), with evidence of effect 
modification (P-homogeneity=0.0053); results were consistent for triglycerides 
(P-homogeneity=0.0101) and directionally similar for non–high-density lipoprotein 
cholesterol (P-homogeneity=0.1387). Last, in adjusted analyses, a 1 SD percentage 
reduction in TRL-C with atorvastatin resulted in a significant lower risk of MACE 
(hazard ratio, 0.93; 95% confidence interval, 0.86–1.00; P=0.0482) independent of 
the reduction in LDL-C and of similar magnitude to that per 1 SD lowering in LDL-C 
(hazard ratio, 0.89; 95% confidence interval, 0.83–0.95; P=0.0008).
CONCLUSIONS: The present post hoc analysis from TNT shows that increased TRL-C 
levels are associated with an increased cardiovascular risk and provides evidence for 
the cardiovascular benefit of lipid lowering with statins among patients who have 
coronary heart disease with high TRL-C.
CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique 
identifier: NCT00327691.
© 2018 American Heart Association, Inc.
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The total cholesterol content in blood can be simply separated into the cholesterol carried by high-den-sity lipoproteins (HDL-C), which principally contain 
apolipoprotein A-I, or the remainder, which is carried 
by a range of atherogenic lipoproteins including low-
density lipoprotein (LDL-C) and triglyceride-rich lipopro-
teins (TRL-C; also referred to in the literature as remnant 
cholesterol) (such as very low-density lipoproteins, inter-
mediate-density lipoproteins, chylomicrons, and their 
remnants), which principally all contain apolipoprotein B 
(apoB) (Figure 1). The total cholesterol content of these 
apoB-containing atherogenic particles can be simply 
calculated by subtracting HDL-C from total cholesterol 
(non-HDL-C); non-HDL-C mostly reflects the cholesterol 
content of LDL; however, the contribution of the choles-
terol carried by TRL particles to non-HDL-C can become 
substantial when triglyceride levels are high.1,2
At a population level, the rising tide of obesity and 
diabetes mellitus and their known association with hy-
pertriglyceridemia may mean that risk algorithms based 
on LDL-C levels only may no longer be sufficient to ap-
propriately measure the atherogenic lipid risk. Indeed, 
there is considerable evidence suggesting that non-
HDL-C is more strongly associated with cardiovascular 
disease (CVD) than LDL-C, both in statin-naive and in 
statin-treated patients.3,4 Furthermore, Mendelian ran-
domization data suggest that TRL-C is a causal factor 
for CVD.5–7 Together with advances in novel therapies 
(such as antisense to apolipoprotein C3 [APOC3] drugs, 
which target TRL-C),8 there is considerable interest in 
whether TRL-C is simply a marker of risk or whether it is 
a modifiable target for therapeutic intervention.
Statins increase the clearance of apoB-containing 
lipoproteins and therefore are expected to not only re-
duce LDL-C levels, but also TRL-C levels. Using data from 
the TNT trial (Treating to New Targets), we assessed the 
relationship between baseline and changes in TRL-C 
and subsequent cardiovascular events. The aims of the 
present analysis specifically assess: (1) whether TRL-C 
is a good marker of risk, (2) whether any excess risk 
related to TRL-C is modifiable by more intensive statin 
therapy, and (3) whether TRL-C is a modifiable target 
for future therapies.
METHODS
The TNT trial has been described in detail elsewhere.9,10 In 
brief, TNT enrolled 35- to 75-year-old men and women with 
clinically evident coronary heart disease (CHD) (defined as 
previous myocardial infarction, previous or present angina 
with objective evidence of atherosclerotic CHD, or a his-
tory of coronary revascularization), and fasting untreated 
(wash-out period where needed) LDL-C 130 to 250 mg/
dL (3.4–6.5 mmol/L) plus triglycerides ≤600 mg/dL (≤6.8 
mmol/L). Of the 18 469 individuals screened, 15 464 met 
the eligibility criteria and entered an 8-week open-label 
run-in phase where all participants were given atorvastatin 
10 mg once daily; after this period, 10 001 participants with 
LDL-C <130 mg/dL (3.4 mmol/L) (on atorvastatin 10 mg), 
absence of adverse events, and compliant with the medica-
tion were subsequently entered the randomized phase and 
were allocated (double-blind) and received atorvastatin 10 
mg (n=5006) or atorvastatin 80 mg (n=4995) once daily 
(Figure I in the online-only Data Supplement).
The TNT primary end point was the time to occurrence of 
a major adverse cardiovascular event (MACE), defined as the 
composite of CHD death, nonfatal non–procedure-related 
myocardial infarction, resuscitated cardiac arrest, or fatal or 
nonfatal stroke. Median follow-up was 4.9 years.
The TNT study was approved by the local research ethics 
committees or institutional review board at each center and 
all patients gave written informed consent.9,10 The TNT trial 
was sponsored by Pfizer. The sponsor did not provide finan-
cial support for the present analysis. Pfizer’s policies on the 
provision of clinical trial data are set out on their website.11 In 
addition to posting clinical trial results on the clinicaltrials.gov 
registry, Pfizer will provide access to anonymized patient-level 
data in response to scientifically valid research protocols.
Clinical Perspective
What Is New?
• Higher levels of triglyceride-rich lipoprotein-cho-
lesterol (TRL-C) are associated with a significantly 
higher rate of cardiovascular events among coro-
nary patients treated with statins.
• Statin therapy reduces TRL-C levels to a higher extent 
among those treated with a higher statin dose.
• We provide evidence from a randomized trial (post 
hoc analysis) that more intensive statin therapy 
with atorvastatin 80 mg, in comparison with ator-
vastatin 10 mg, results in a significantly greater 
cardiovascular risk reduction among patients with 
higher TRL-C levels. Results were consistent for 
higher triglycerides and directionally concordant 
for non–high-density lipoprotein cholesterol.
• A higher percentage reduction in TRL-C levels was 
associated with lower cardiovascular risk inde-
pendently of low-density lipoprotein cholesterol 
reduction.
What Are the Clinical Implications?
• Our data support those from observational and 
genetic studies suggesting that TRL-C is a risk fac-
tor for cardiovascular disease.
• In addition, the present analysis suggests a car-
diovascular benefit of lipid-lowering medication 
among those with higher TRL-C levels.
• Taken together, the present results suggest that TRL-C 
levels are not only a cardiovascular risk marker, but 
also a potential target for therapeutic intervention.
• These data provide the rationale for the development 
of drugs aiming to reduce triglycerides and TRL-C; 
that may include novel agents under development 
targeting angiopoietin-like 3 or apolipoprotein C3.
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Present Analyses
Among TNT participants who entered the randomized trial 
(n=10 001), 9993 (99.9%) had data on TRL-C levels at 
baseline, ie, at the time of randomization (atorvastatin 10 
mg, n=5003; atorvastatin 80 mg, n=4990) (Figure I in the 
online-only Data Supplement), and were included in the 
present analyses. TRL-C levels were calculated as the differ-
ence between fasting non-HDL-C and LDL-C. Non-HDL-C 
was defined as total cholesterol minus HDL-C. LDL-C was 
calculated using the Friedewald formula12 (unless triglycer-
ide levels were ≥400 mg/dL [≥4.5 mmol/L], where LDL-C was 
directly measured by ultracentrifugation). These calculated 
TRL-C levels have been reported to closely approximate the 
levels of triglycerides.13
In the present analyses, the effect of atorvastatin 10 mg 
on TRL-C levels was assessed during the open-label run-in 
phase, and that of atorvastatin 80 mg versus 10 mg over 5 
years was assessed during the randomized phase, to deter-
mine if a dose-dependent effect on TRL-C levels exists. The 
risk of MACE was assessed across quintiles of baseline TRL-C 
levels during the randomized period. Last, observational 
analyses were performed to elucidate the extent to which the 
reductions achieved with atorvastatin in TRL-C levels influ-
ence outcomes.
Further details on methods are shown in Methods in the 
online-only Data Supplement  and Figure I in the online-only 
Data Supplement.
Statistical Analysis
Mean TRL-C levels during the trial are shown as mean±SD 
and median, interquartile range. Patients were grouped by 
quintiles of TRL-C at baseline (ie, at the time of randomiza-
tion). The characteristics of participants were compared across 
quintiles as follows: the Cochran-Mantel-Haenszel statistics 
(Cochran-Armitage Trend Test) were used for categorical vari-
ables, and regression analysis was conducted for continuous 
variables with quintile as a continuous variable in the model.
Effect of Statin Therapy on Outcomes
The randomized effect of atorvastatin 80 mg in compari-
son with atorvastatin 10 mg on the risk of MACE was 
assessed for each quintile of TRL-C at baseline. Absolute 
risk reductions and numbers needed-to-treat were calcu-
lated based on the event rates in both arms where appropri-
ate. Estimates of hazard ratios (HRs) and 95% confidence 
intervals (95% CIs) with corresponding P values for each 
quintile were obtained by Cox-regression analysis, with ran-
domized therapy as the only covariate. To assess whether 
the effect of atorvastatin 80 mg versus 10 mg was consis-
tent across TRL-C quintiles, a test for interaction was per-
formed (test for homogeneity). By way of comparison, the 
same estimates were obtained for quintiles of triglycerides 
and quintiles of non-HDL-C at baseline.
Changes in TRL-C Levels and On-Treatment TRL-C 
and Outcomes
The independent association between the absolute and rel-
ative change in TRL-C levels from baseline to 3 months and 
the on-treatment TRL-C levels with the subsequent cardio-
vascular risk were assessed by means of multivariable Cox-
regression models. On-treatment TRL-C levels were defined 
as levels at month 3 after randomization. Participants with 
events before 3 months were excluded for these analy-
ses. TRL-C levels were entered as log-transformed values 
(to normalize the distribution of the variable to include it 
in the model). Adjusted HR (95% CI) and corresponding 
P values were calculated per 1 SD change/on-treatment 
TRL-C. Multivariable models accounted for the following 
covariates: age, sex, smoking status, hypertension, diabe-
tes mellitus, prior myocardial infarction, baseline log(TRL-
C), LDL-C and HDL-C, and absolute change or percentage 
change or on-treatment (as appropriate) LDL-C and HDL-C 
levels. By way of comparison, the same estimates were 
obtained for LDL-C levels, and similar models were built 
for triglycerides (log-transformed) and for non-HDL-C lev-
els (replacing TRL-C by the corresponding lipid fraction; in 
the case of non-HDL-C, LDL-C levels were not included in 
the models to avoid colinearity because LDL-C is contained 
in non-HDL-C).
The statistical analyses were performed using SAS soft-
ware, versions 9.2/9.3 (SAS Institute Inc). Tests were 2-sided. 
Statistical significance was defined as P<0.05. Trial registra-
tion: ClinicalTrials.gov, NCT00327691.
Figure 1. Lipoprotein particles. 
ApoA indicates apolipoprotein A; ApoB, 
apolipoprotein B; HDL, high-density lipoprotein; 
IDL, intermediate-density lipoprotein; LDL, low-
density lipoprotein; TRL, triglyceride-rich lipo-
protein; and VLDL, very low-density lipoprotein.
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RESULTS
Impact of Statins on TRL-C
Mean (±SD) TRL-C level at the beginning of the run-in 
phase was 33.9±16.6 mg/dL (0.9±0.4 mmol/L). Atorv-
astatin 10 mg reduced TRL-C levels during the run-in 
phase by a median of 10.7% (median absolute change, 
–3.0 mg/dL [–0.1 mmol/L]; interquartile range, –10.0 
to 3.0 mg/dL [–0.3 to 0.1 mmol/L]; P<0.0001). This re-
duction remained similar throughout the study in those 
allocated to atorvastatin 10 mg during the randomized 
period (Figure 2). In those allocated to atorvastatin 80 
mg after the initial run-in phase with 10 mg, TRL-C was 
reduced by a further 15.4% (median absolute change, 
–4.0 mg/dL [–0.1 mmol/L]; interquartile range, –9.0 to 
1.0 mg/dL [–0.2 to 0.0, mmol/L]; P<0.0001). The time-
course levels of TRL-C during the randomized phase are 
shown in Figure 2. Median levels of TRL-C were lower 
in the group of patients allocated to atorvastatin 80 mg 
throughout the randomized trial (Figure 2 and Figure II 
in the online-only Data Supplement). The time-course 
levels of LDL-C by treatment arm are shown in Figure III 
in the online-only Data Supplement.
Demographics Across TRL-C Quintiles
The characteristics of participants by TRL-C quintiles 
at baseline are shown in the Table (the quantiles cor-
responded to TRL-C levels of 19.0, 24.0, 30.0, and 
39.5 mg/dL [0.5, 0.6, 0.8, and 1.0 mmol/L]). Patients in 
lower quintiles were slightly older and more frequent-
ly men than those in higher quintiles (62.0±8.6 years 
and 86.6% men in quintile 1 versus 59.5±8.9 years 
and 76.6% men in quintile 5; P<0.0001 for trend). It 
is notable that the presence of cardiovascular risk fac-
tors such as hypertension, diabetes mellitus and levels 
of fasting glucose, smoking, body mass index, and an 
unfavorable lipid profile (higher total cholesterol, LDL-
C, non-HDL-C and triglycerides, and lower HDL-C) posi-
tively correlated with levels of TRL-C (all P<0.0001 for 
trend across quintiles). Although LDL-C levels were sig-
nificantly higher for quintile 5 than for quintile 1 (mean 
99.1±18 versus 94.2±17 mg/dL [2.6±0.5 versus 2.4±0.4 
mmol/L]), this difference was substantially less marked 
than that observed for non-HDL-C (150.8±21 versus 
109.9±17 mg/dL [3.9±0.5 versus 2.8±0.4 mmol/L]) or 
for TRL-C (51.7±10.8 versus 15.7±2.5 mg/dL [1.3±0.3 
versus 0.4±0.1 mmol/L]).
TRL-C Levels and Outcomes
Among patients receiving atorvastatin 10 mg, higher 
TRL-C levels were associated with higher rates of MACE 
at 5 years, ranging from 9.7% in quintile 1 to 13.8% 
in quintile 5; HR for quintile 5 versus quintile 1, 1.48 
(95% CI, 1.15–1.92); P for trend quintile 1 to quintile 
5 <0.0001 (Figure 3). Among patients receiving atorv-
astatin 80 mg, baseline TRL-C levels were not associ-
ated with outcomes (P for trend quintile 1 to quintile 5, 
P=0.7806; Table I in the online-only Data Supplement).
Effect of Statin Therapy on Outcomes
Figure 4A depicts the effect of atorvastatin 80 mg ver-
sus 10 mg on the risk of MACE by quintiles of TRL-C 
at baseline. In the lowest 2 quintiles there was no sig-
nificant benefit from atorvastatin 80 mg on cardiovas-
cular outcomes in comparison with atorvastatin 10 mg. 
However, with increasing levels of TRL-C there was evi-
dence of effect modification (P-homogeneity 0.0053) 
Figure 2. Time course levels of triglyceride-rich lipoprotein (TRL) cholesterol grouped by treatment arm. 
Data shown as mean± SD and median (interquartile range [IQR]). *All patients received atorvastatin 10 mg/d during the 8-week run-in phase. To convert cholesterol 
values from mg/dL to mmol/L, multiply by 0.02586. TRL indicates triglyceride-rich lipoprotein.
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with significant risk reductions observed in quintiles 
3 to 5. Absolute risk reductions  of 2.4%, 4.7%, and 
3.9% were observed in quintiles 3, 4, and 5, respective-
ly, corresponding to 5-year numbers needed-to-treat of 
42, 21, and 26, respectively.
Changes in TRL-C Levels and Outcomes
In fully adjusted analyses, the percentage reduction in 
TRL-C from baseline to 3 months was associated with 
the risk of MACE independent of the reduction in LDL-C 
(Figure 5). The benefit observed with a 1 SD percentage 
lowering of log(TRL-C) (HR, 0.929; P=0.0482; 1 SD=9.0 
[raw value=30.2]) was independent of LDL-C and was 
of similar magnitude to that associated with a 1 SD 
percentage lowering of LDL-C (HR, 0.890; P=0.0008; 
1 SD=22.1) in models that contained both TRL-C and 
LDL-C. For comparison, the analysis of absolute change 
in levels of log(TRL-C) and on-treatment log(TRL-C) lev-
els and risk of outcomes provided qualitatively similar 
findings, although these were not statistically signifi-
cant (HR, 0.934, P=0.0650, and HR 0.900, P=0.0650, 
respectively) (Figure 5).
Comparative Analyses With Triglycerides 
and Non-HDL-C Replacing TRL-C
Baseline TRL-C levels correlated well with triglycerides 
and non-HDL-C levels (Pearson correlation coefficients: 
log[TRL-C] and log[triglycerides]: r=0.99, P<0.001; 
log[TRL-C] and non-HDL-C: r=0.64, P<0.001).
In analyses of risk of MACE with more versus less in-
tensive statin therapy by baseline quintiles of triglycer-
ides and treatment interactions, we observed a similar 
relationship as with TRL-C, with a significant P value 
for interaction of P=0.0101 (Figure  4B). Analyses of 
risk by baseline quintiles of non-HDL-C showed results 
directionally similar to those from TRL-C and triglycer-
ides, although the magnitude of effect was somewhat 
attenuated and there was no interaction by treatment 
(P=0.1387) (Figure 4C).
In analysis assessing reductions in triglycerides, we 
observed qualitatively similar percentage risk reduc-
tions as with TRL-C (although in the case of triglycer-
ides, these risk reductions did not reach the nominal 
level of statistical significance when LDL-C was in-
cluded in the models; percentage change, absolute 
change, or on-treatment triglycerides levels, all per 1 
SD lower in log[triglycerides]: HR 0.93 [P=0.0562], HR 
0.94 [P=0.0784], and HR 0.91 [P=0.0784], respectively; 
Figure IV in the online-only Data Supplement). By way 
of comparison, analyses based on reductions in non-
HDL-C levels led to stronger and significant risk reduc-
tions (HRs ranging from 0.84 to 0.87 per 1 SD lower of 
non-HDL-C, all P<0.0001; Figure V in the online-only 
Data Supplement).
DISCUSSION
The present analysis from the TNT trial in ≈10 000 pa-
tients with CHD receiving atorvastatin suggests a great-
er benefit of lipid-lowering therapy on cardiovascular 
Table. Baseline Characteristics of Participants, by Quintiles of Triglyceride-Rich Lipoprotein Cholesterol at Baseline
 
Triglyceride-Rich Lipoprotein Cholesterol, by Baseline Quintiles
P Value
≤19.0 mg/dL >19.0–24.0 mg/dL >24.0–30.0 mg/dL >30.0–39.5 mg/dL >39.5 mg/dL
n=2125 n=1951 n=1991 n=1966 n=1960
Age, y 62.0±8.6 61.6±8.8 61.6±8.7 60.3±8.9 59.5±8.9 <0.0001
Sex: male 1820 (85.6) 1619 (83.0) 1608 (80.8) 1544 (78.5) 1501 (76.6) <0.0001
Hypertension 1017 (47.9) 974 (49.9) 1126 (56.5) 1093 (55.6) 1200 (61.2) <0.0001
Diabetes mellitus 228 (10.7) 225 (11.5) 280 (14.1) 347 (17.6) 420 (21.4) <0.0001
Current smokers 260 (12.2) 251 (12.9) 225 (11.3) 287 (14.6) 316 (16.1) <0.0001
Prior myocardial infarction 1253 (59.0) 1141 (58.5) 1145 (57.5) 1150 (58.5) 1138 (58.1) 0.9081
Body mass index, kg/m2 27.0±3.9 27.8±4.2 28.6±4.8 29.3±4.6 30.0±4.7 <0.0001
Glucose, mg/dL 102.8±25.6 103.7±24.9 106.4±27.6 110.6±33.3 115.5±38.0 <0.0001
Total cholesterol, mg/dL 163.0±21.6 168.7±21.2 171.7±20.9 178.5±20.8 192.9±23.1 <0.0001
HDL cholesterol, mg/dL 53.0±12.0 49.4±10.9 46.9±9.9 44.7±9.4 42.0±8.7 <0.0001
LDL cholesterol, mg/dL 94.2±16.7 97.5±17.6 97.7±17.1 99.2±17.7 99.1±18.5 <0.0001
Non–HDL cholesterol, mg/dL 109.9±17.1 119.2±17.6 124.8±17.3 133.8±17.9 150.8±21.5 <0.0001
Triglycerides, mg/dL 80.5 (70.0–89.0) 108.5 (102.5–115.0) 135.5 (128.0–143.0) 172.0 (160.5–184.5) 244.5 (217.5–287.8) <0.0001
TRL cholesterol, mg/dL 15.7±2.5 21.7±1.4 27.1±1.7 34.6±2.7 51.7±10.8 <0.0001
Data shown as absolute and relative (%) numbers for qualitative variables; quantitative variables are shown as mean±SD, or as median and interquartile range, 
as appropriate. To convert cholesterol and triglycerides values from mg/dL to mmol/L, multiply by 0.02586 and 0.01129, respectively. HDL indicates high-density 
lipoprotein; LDL, low-density lipoprotein; and TRL, triglyceride-rich lipoprotein.
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outcomes among those with higher TRL-C levels. The 
present analyses revealed that (1) higher TRL-C levels 
were associated with a higher prevalence of cardiovas-
cular and metabolic risk factors; (2) treatment with ator-
vastatin significantly reduced TRL-C levels, to a greater 
extent in those treated with the highest statin dose; (3) 
higher TRL-C levels were associated with a higher rate 
of cardiovascular events at 5 years; (4) evidence from a 
randomized trial that more intensive statin therapy with 
atorvastatin 80 mg, in comparison with atorvastatin 10 
mg, resulted in a significantly greater cardiovascular risk 
reduction among those patients with higher TRL-C lev-
els (those in TRL-C quintiles 3–5 versus 1–2; significant 
interaction of statin intensity by TRL-C quintiles); the 
results for this analysis were consistent for TRL-C and 
triglyceride levels, and directionally similar for non-HDL-
C; (5) observational evidence that a 1 SD percentage 
reduction in TRL-C levels with atorvastatin was associ-
ated with a lower risk of MACE independent of and of 
similar magnitude to a 1 SD reduction in LDL-C levels.
The present results fit well with previous reports 
from the TNT trial. For instance, patients with metabolic 
syndrome in the TNT trial have been observed to obtain 
more benefit from high-dose atorvastatin than did pa-
tients without metabolic syndrome,14 which likely track 
with higher levels of TRL-C (and non-HDL-C and triglyc-
erides) among those subjects with metabolic syndrome. 
These results are also concordant with the increased 
risk associated with higher triglyceride levels in the 
combined cohorts from the TNT trial and the IDEAL trial 
(Incremental Decrease in End Points through Aggres-
sive Lipid Lowering).15 Of interest, on the other hand, 
the present analysis revealed differences between treat-
ment groups (statistically significant treatment-by-quin-
tile interaction) when the data were stratified by TRL-C 
or triglyceride quintiles. This is unlike previous analysis 
from the TNT trial, which did not find differences be-
tween groups (no interaction) based on LDL-C levels.16 
In the same direction, in the Cholesterol Treatment Tri-
alists meta-analysis, the relative risk reduction of major 
vascular events with statins per 39 mg/dL increase in 
LDL-C remained constant among different strata based 
on triglycerides levels.17 Thus, our results support the 
notion that intensive lipid-lowering medication among 
those with higher TRL-C is of benefit for CV risk re-
duction; whether further intensive lipid lowering, eg, 
with PCSK9 (proprotein convertase subtilisin/kexin type 
9) inhibitors, leads to further benefit based on baseline 
TRL-C levels requires further research.
Despite optimal therapy with high-intensity statin 
regimes to lower LDL-C,10,18 and, more recently, with 
the combination therapy of statins with ezetimibe19 or 
PCSK9 inhibitors20,21 to further lower LDL-C levels, a 
significant residual risk of CVD still persists. TRL-C may 
account, at least in part, for this residual risk. In fact, in 
our study, among coronary patients with an initial LDL-
C <130 mg/dL (3.4 mmol/L) who were subsequently 
treated with atorvastatin 10 mg, we observed a sig-
nificant higher risk of cardiovascular events with higher 
TRL-C levels (HR for quintile 5 versus quintile 1, 1.48; 
95% CI, 1.15–1.92). Among participants in the high-in-
tensity statin group (atorvastatin 80 mg), where a simi-
lar relationship was not observed among quintiles of 
TRL-C, TRL-C levels might be unlikely to predict future 
risk, because at least part of the excess risk (residual 
risk) is attenuated by receiving high-intensity therapy. In 
Figure 3. Risk of major cardiovascular events among patients receiving atorvastatin 10 mg based on quintiles of triglyceride-rich lipoprotein choles-
terol at baseline. 
To convert cholesterol values from mg/dL to mmol/L, multiply by 0.02586. CI indicates confidence interval; HR, hazard ratio; and TRL-C, triglyceride-rich lipoprotein 
cholesterol.
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Figure 4. Effect of atorvastatin 80 mg versus atorvastatin 10 mg on the risk of major cardiovascular events by quintiles of triglyceride-rich lipopro-
tein cholesterol (A), triglycerides (B), and non-HDL-C (C) at baseline. 
To convert cholesterol values from mg/dL to mmol/L, multiply by 0.02586. To convert triglyceride values from mg/dL to mmol/L, multiply by 0.01129. ATV indicates 
atorvastatin; CI, confidence interval; HR, hazard ratio; non-HDL-C, non–high-density lipoprotein cholesterol; TG, triglycerides; and TRL-C, triglyceride-rich lipopro-
tein cholesterol.
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contrast, among patients on atorvastatin 10 mg, higher 
TRL-C levels may represent a clinical group with higher 
residual risk in need of further lipid-lowering therapy. 
These results are in agreement with those reported by 
different observational studies, where elevated TRL-C 
levels have been associated with increased cardiovascu-
lar risk, mainly with CHD.2,22 For instance, fasting TRL-
C has recently been associated with the presence and 
severity of coronary artery calcium score independently 
of classical risk factors, including HDL-C and LDL-C, in a 
cohort of >3800 asymptomatic subjects without history 
of CVD from the ELSA-Brasil Study (Brazilian Longitudi-
nal Study of Adult Health).22 In addition, observational 
data from a large cohort of >73 500 subjects from the 
general population in Denmark reported an increased 
risk for CHD with increasing levels of TRL-C (P<0.001 
for trend from quintile 1 to quintile 5)2; it is interest-
ing to note that HRs were significant only among those 
within higher levels of TRL-C in comparison with those 
in the lower stratum (quintiles 4 and 5 [TRL-C >27 mg/
dL, >0.7 mmol/L] versus quintile 1 [<15 mg/dL, <0.4 
mmol/L]); HRs 2.0 [95% CI, 1.5–2.6] and 2.3 [95% CI, 
1.7–3.1], respectively), but not among those in quintiles 
2 and 3 versus quintile 1. These data are in the same di-
rection as the results we have found in our study, where 
the cardiovascular benefit of more intensive statin ther-
apy reached significance among those within quintiles 
3 to 5 only (TRL-C >24.0 mg/dL [>0.6 mmol/L], thus 
with a threshold similar to that in the Danish study). 
More recently, an association of increased remnant cho-
lesterol levels with all-cause mortality in patients with 
CHD has also been reported from the Copenhagen 
Ischemic Heart Disease Study (unlike increased mea-
sured LDL-C levels).23
In addition to observational studies suggesting a 
positive association between TRL-C and cardiovascular 
risk, a number of genetic studies has strongly support-
ed higher TRL-C or triglyceride levels to be a causal risk 
factor for CVD.24 For instance, Mendelian randomiza-
tion analysis from the aforementioned Danish cohort 
found a significant 2.8-fold causal risk for CHD per 39 
mg/dL (1.0 mmol/L) increase in nonfasting TRL-C, in-
dependent of LDL-C or HDL-C, and higher than that 
observed per similar increase in LDL-C.2 Different ge-
netic variants have further supported these observa-
tions. This is the case for the loss-of-function mutations 
in genes encoding ANGPTL3 (angiopoietin-like 3) and 
ANGPTL4 (angiopoietin-like 4) proteins25,26 or loss-of-
function or missense mutations in the APOC3 gene6; 
these genetic variants have been associated with sub-
stantially decreased levels of triglycerides, and carriers 
of these mutations have an associated lower rate of 
ischemic coronary or vascular disease.5,6,25,26 Thus, these 
genetic variants related to lower levels of triglycerides 
seem to confer reduced genetic risk for CVD, a likely 
causal relationship.
The present analysis from the TNT trial complements 
and adds to the current available information from ob-
Figure 5. Association between TRL-C and LDL-C level reduction or on-treatment TRL-C and LDL-C levels and risk of major cardiovascular events. 
On-treatment levels are defined as levels at 3 months of therapy (randomized trial). The analysis excludes patients with events before 3 months. A 1 SD of percent-
age change in log(TRL-C) and of absolute change in log(TRL-C) from baseline to month 3 corresponds to 9.0 and 0.3, respectively (raw [log back] values: 30.2 
and 9.6, respectively). A 1 SD of on-treatment log(TRL-C) levels corresponds to 0.4 (raw [log back] value, 13.8). The corresponding values for a 1 SD percentage 
change and absolute change in LDL-C levels and on-treatment LDL-C levels are 22.1, 21.4, and 24.5, respectively. Multivariate analysis adjusted for age, sex, 
smoking, hypertension, diabetes mellitus, myocardial infarction, baseline log(TRL-C), baseline LDL-C, baseline high-density lipoprotein cholesterol, and changes or 
on-treatment lipid levels as appropriate. Number of patients with on-treatment TRL-C data: atorvastatin 10 mg, n=4895; atorvastatin 80 mg, n=4874. To convert 
cholesterol and triglyceride values from mg/dL to mmol/L, multiply by 0.02586 and 0.01129, respectively. LDL-C indicates low-density lipoprotein cholesterol; and 
TRL-C, triglyceride-rich lipoprotein cholesterol.
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servational and genetic studies supporting the role of 
TRL-C on cardiovascular risk, by providing novel evi-
dence from a randomized trial, not available so far, on 
the benefit of lipid-lowering medication among those 
with higher TRL-C. As such, therapy with atorvastatin 
80 mg, in comparison with atorvastatin 10 mg, led to 
a significant 5-year relative risk reduction of MACE 
among those with TRL-C >24.0 mg/dL (0.6 mmol/L) 
ranging from 29% to 41%, which corresponded to ab-
solute risk reductions of 2.4% to 4.7%. These results 
were consistent with those observed using triglyceride 
levels and directionally similar for non-HDL-C levels 
(see discussion below). Among the overall cohort of 
patients, the risk reduction associated with a 1 SD per-
centage reduction of TRL-C levels from baseline cor-
responded to a HR of 0.929 (P=0.0482), which was 
independent of LDL-C levels and comparable to that 
risk reduction achieved with a 1 SD percentage reduc-
tion in LDL-C (HR 0.890, P=0.0008). In similar analysis, 
reductions in non-HDL-C levels led to slightly stronger 
risk reductions than TRL-C and comparable to LDL-C 
(HR 0.866 per 1 SD percentage reduction in non-HDL-
C, P<0.0001), in line with previous reports where non-
HDL-C has been strongly associated with cardiovas-
cular events (even stronger than LDL-C levels) among 
patients treated with statins.4
The mechanism by which elevated TRL-C leads to 
more MACE and why reducing it is associated with low-
er rates of MACE merit consideration. Figure 6 shows 
causal pathways by which LDL particles (cholesterol con-
tent of LDL) and triglyceride-related pathways (whether 
through triglycerides or TRL-C) increase cardiovascular 
risk. Our data cannot separate whether triglycerides 
or TRL-C is the causal factor of this triglyceride-relat-
ed pathway (because TRL-C, as calculated from other 
lipid fractions, closely approximates to triglycerides 
divided by 5); however, biologically, triglycerides have 
not been directly implicated in the process of athero-
sclerosis, whereas cholesterol is clearly causal.27 It has 
been suggested that, when plasma TRL-C is elevated, 
more TRLs enter from plasma into the arterial intima, 
which in turn lead to uptake and degradation of TRLs 
by monocyte-macrophages and consequently increase 
the cholesterol deposits in the atherosclerotic plaques; 
such inflamed plaques are more likely to rupture and 
cause MACE.24 The role of TRL-C as an important factor 
in atherosclerotic CVD is also supported by the stronger 
risk reductions for non-HDL-C that contains both LDL-C 
and TRL-C in comparison with LDL-C. This is consistent 
with other analyses from statin trials.4
The relationship of TRL-C levels with atherosclerotic 
CVD risk is of particular importance considering the rise 
in prevalence of cardiometabolic risk conditions such 
as diabetes mellitus, obesity, or metabolic syndrome, 
which are frequently associated with a characteristic 
dyslipidemia that includes increased TRL-C levels along 
with high triglycerides and non-HDL-C and low HDL-
C.28 This has led to a renewed interest in medication 
that may effectively reduce triglycerides and TRL-C lev-
els, and the present results from the TNT trial provide 
a rationale for this type of intervention. That includes 
novel agents under development targeting ANGPTL3 
(human monoclonal antibody against Angptl3, evi-
nacumab, or antisense oligonucleotides against Ang-
ptl3 messenger-RNA)25,29 or APOC3 (antisense inhibitor 
of APOC3 synthesis).8 The first observations in humans 
have demonstrated that these agents substantially re-
duce the levels of triglycerides in comparison with pla-
cebo.8,25,29 Whether this effect will translate into the 
reduction of cardiovascular risk has not been addressed 
by the current available studies.
To date, there are no large randomized controlled 
trial data that have convincingly showed that lowering 
triglycerides reduces cardiovascular events, apart from a 
Figure 6. Causal pathways by which LDL particles (cholesterol content of LDL) and triglyceride-related pathways (whether through triglycerides or 
TRL-C) increase cardiovascular risk. 
ApoB indicates apolipoprotein B; CV, cardiovascular; IDL, intermediate-density lipoprotein; non-HDL-C, non–high-density lipoprotein cholesterol; LDL(-C), low-
density lipoprotein (cholesterol); TRL(-C), triglyceride-rich lipoprotein (cholesterol); and VLDL, very low-density lipoprotein.4,24,27
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meta-analysis of randomized trials of fibrates versus pla-
cebo that reported a reduction of CHD events by 35% 
with fibrates among patients with high triglycerides 
and low HDL-C.30 Several randomized clinical trials aim-
ing specifically at patients with hypertriglyceridemia are 
currently ongoing, using omega-3 therapies (REDUCE-
IT [Reduction of Cardiovascular Events with Icosapent 
Ethyl-Intervention Trial],31 STRENGTH [Outcomes Study 
to Assess Statin Residual Risk Reduction With EpaNova 
in High CV Risk Patients With Hypertriglyceridemia]32) 
or the novel selective peroxisome proliferator-activated 
receptor alpha modulator pemafibrate (PROMINENT 
[Pemafibrate to Reduce Cardiovascular Outcomes by Re-
ducing Triglycerides in Patients With Diabetes]33). These 
trials may provide further insights regarding the cardio-
vascular benefit of triglycerides and TRL-C lowering (in-
dependently of LDL-C) or non-HDL-C lowering on car-
diovascular outcomes. With respect to PCSK9 inhibitors, 
they have shown in randomized trials of patients with 
high/not-on-target LDL-C, usually on top of statins, to 
substantially reduce apoB levels by ≈50% in comparison 
with controls, but their effect on triglyceride levels is far 
more limited34; to what extent this translates into TRL-C 
reduction (the cholesterol carried by apoB-related parti-
cles, and so by TRL-C, could be reduced by increasing the 
clearance of these particles),35 and the latter into cardio-
vascular risk reduction, is currently under investigation.
Some limitations of the present analysis require con-
sideration. For instance, although these analyses are 
from a randomized trial, they are post hoc analyses. The 
analyses based on changes in TRL-C levels and on-treat-
ment TRL-C are observational in nature. Where applica-
ble, the analyses have been adjusted for different base-
line characteristics, although we cannot fully rule out the 
potential for confounding factors affecting the results. 
TRL-C levels were estimated from the levels of other lipid 
fractions as total cholesterol minus HDL-C minus LDL-
C, where LDL-C was mostly estimated by the Friedewald 
formula, with no direct measurement of TRL-C; these 
calculated TRL-C levels have been reported to closely ap-
proximate the total content of triglycerides in blood and 
suggested that, in practice, the associations found might 
also be primarily with triglycerides13; this aligns with the 
strong correlation observed between calculated TRL-C 
and triglyceride levels in our study (r=0.99, P<0.001) and 
the results reported in a previous study by Varbo et al2 
(R2 0.96, P<0.001); nevertheless, this methodology has 
been previously reported in prior studies and, more im-
portant, this calculated TRL-C has been related to CVD 
in different studies as previously discussed.2,22,23 In the 
future it will be possible to measure TRL-C directly to 
further validate these findings.36 Last, our analyses are 
based on fasting TRL-C levels; thus, although we do not 
expect our results to materially change and be similarly 
applicable to TRL-C levels measured during the nonfast-
ing state (because they are in the same direction as those 
studies using nonfasting TRL-C), we cannot confirm they 
can be fully extrapolated to nonfasting TRL-C.
In summary, the present analysis from the random-
ized TNT trial shows that TRL-C levels are reduced by 
atorvastatin therapy in a dose-dependent fashion. 
Although higher TRL-C levels are associated with in-
creased CVD risk, our results provide evidence for this 
cardiovascular risk to be significantly attenuated by in-
tensive atorvastatin therapy in those with higher TRL-C 
levels (with consistent results for higher triglyceride lev-
els and directionally concordant relationship for higher 
non-HDL-C levels). Independent of the reduction in 
LDL-C, the percentage reduction in TRL-C was associ-
ated with cardiovascular events. Taken together, these 
data suggest that TRL-C levels are both a risk marker 
and a potential target for therapeutic intervention.
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